【疗效碾压阿斯利康(AZN.US)Imfinzi!Summit(SMMT.US)依沃西单抗III期试验数据积极,股价应声大涨】智通财经APP获悉,周三美股盘前,Summit
Therapeutics(SMMT.US)股价一度大涨逾16%,此前该公司公布了后期试验的积极数据。结果显示,其核心候选药物依沃西单抗(ivonescimab,由合作伙伴康方生物(09926.HK)授权引进)在疗效上超越了阿斯利康(AZN.US)旗下的癌症药物Imfinzi(通用名:度伐利尤单抗)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.